Total Liabilities (Quarterly) Chart

View Total Liabilities (Quarterly) for CYPH.
Upgrade now.
Sep '18
Jan '19
May '19
 
285.00
270.00
255.00
240.00
View Total Liabilities (Quarterly) Chart
Start Trial

Historical Total Liabilities (Quarterly) Data

View and export this data back to 2017. Start Trial.
Date Value
June 30, 2026 3.65M
March 31, 2026 3.003M
December 31, 2025 18.14M
September 30, 2025 8.704M
June 30, 2025 14.32M
March 31, 2025 14.04M
December 31, 2024 14.08M
September 30, 2024 16.09M
June 30, 2024 15.64M
March 31, 2024 10.59M
December 31, 2023 12.68M
September 30, 2023 11.04M
June 30, 2023 11.80M
March 31, 2023 10.50M
December 31, 2022 11.49M
September 30, 2022 12.09M
June 30, 2022 10.88M
March 31, 2022 7.344M
December 31, 2021 10.02M
Date Value
September 30, 2021 11.26M
June 30, 2021 8.056M
March 31, 2021 7.428M
December 31, 2020 7.72M
September 30, 2020 7.406M
June 30, 2020 7.94M
March 31, 2020 10.78M
December 31, 2019 9.197M
September 30, 2019 8.579M
June 30, 2019 9.198M
March 31, 2019 9.019M
December 31, 2018 9.899M
September 30, 2018 20.50M
June 30, 2018 22.27M
March 31, 2018 22.56M
December 31, 2017 17.94M
September 30, 2017 5.994M
June 30, 2017 4.375M
March 31, 2017 4.612M

Total Liabilities Definition

Liabilities are a main portion of the balance sheet of a company that measure outstanding payables/obligations. A few examples of liabilties of a company include accounts payable, current debt, and capital lease obligations. From an accounting perspective, the balance sheet equation is Liabilties = Assets - Shareholder's Equity.

Read full definition.

Total Liabilities (Quarterly) Range, Past 5 Years

View Total Liabilities (Quarterly) Range, Past 5 Years
Start Trial
--
Minimum
--
Maximum
--
Average
--
Median

Total Liabilities (Quarterly) Benchmarks

View Total Liabilities (Quarterly) Benchmarks
Start Trial
Indaptus Therapeutics, Inc. 0.6154M
ACADIA Pharmaceuticals, Inc. 436.29M
Alnylam Pharmaceuticals, Inc. 4.205B
Anika Therapeutics, Inc. 46.19M
Savara, Inc. 48.48M

Total Liabilities (Quarterly) Related Metrics